Li, Tianjing
McCann, Paul M.
Wilting, Sarah
McNamara, Steve
Gregory, Darren G.
Hauswirth, Scott G.
Ifantides, Cristos
Benning, Lorie
Sequeira, Tamara A.
Qureshi, Riaz
Liu, Su-Hsun
Clark, Melissa A.
Saldanha, Ian J.
Abraham, Alison G.
Funding for this research was provided by:
National Eye Institute, National Institutes of Health (UG1 EY020522-13S1, UG1 EY020522-13S1, UG1 EY020522-13S1, UG1 EY020522-13S1, UG1 EY020522-13S1, UG1 EY020522-13S1, UG1 EY020522-13S1, UG1 EY020522-13S1, UG1 EY020522-13S1, UG1 EY020522-13S1, UG1 EY020522-13S1, UG1 EY020522-13S1, UG1 EY020522-13S1, UG1 EY020522-13S1)
Article History
Received: 5 June 2023
Accepted: 25 September 2023
First Online: 19 October 2023
Declarations
:
: The Colorado Multiple Institutional Review Board approved the study (IRB protocol number: 21-2541). The study was carried out in accordance with relevant guidelines and regulations established in 45 Code of Federal Regulations 46. During the measurement visit, the study coordinator obtained written informed consent from participants.
: Not applicable.
: DG has the following disclosures: Claris Biotherapeutics (I), Oyster Point Pharma (I), Sylentis (I)SH has the following disclosures: Allergan/Abbvie (C), BioTissue, Inc (C), Claris Biotherapeutics (I), TearScience, Inc (C), Johnson & Johnson Vision (C), Novartis (C), Sun Pharmaceuticals (C), TearRestore (C/I), Sight Sciences (C), Kala Pharmaceuticals (C), Dompe USA (C/I), Horizon Therapeutics (C), Science Based Health (C), Ocular Therapeutix (C/I), Nusight Medical (C), Oyster Point Pharma (C/I), Thea Pharma (C)CI has the following disclosures: AbbVie: C; Ace Vision Group: C; AcuFocus, Inc.: C; Alcon Laboratories, Inc.: C; Bausch and Lomb: I; BVI: C; Centricity Vision: C; Hu-Med Technologies LLC: C,P; Johnson & Johnson: C,S; New World Medical, Inc.: P,I; Spect, Inc.: C; Tarsus: C; Trefoil: C; Vision 2020 USA: C; Visus Therapeutics: C; Zeiss: C,I.C = paid consultant I = InvestigatorP = Intellectual Property. All other authors declared no competing interests.